

27. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al; SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. *N Engl J Med*. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. PMID: 33200891.
28. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. *N Engl J Med*. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. PMID: 33200892.
29. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors – Lessons From a Case Series and Strategies to Decrease Incidence. *Endocr Pract*. 2022 Sep;28(9):884-888. doi: 10.1016/j.eprac.2022.06.006. Epub 2022 Jun 23. PMID: 35753675.
30. Iwasaki Y, Sasabuchi Y, Horikita S, Furukawa T, Shiotsuka J, Lefor AK, et al. The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study. *BMC Endocr Disord*. 2022 Aug 20;22(1):209. doi: 10.1186/s12902-022-01126-z. PMID: 35987618; PMCID: PMC9392326.
31. Steinhorn B, Wiener-Kronish J. Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis. *Br J Anaesth*. 2023 Oct;131(4):682-686. doi: 10.1016/j.bja.2023.06.063. Epub 2023 Aug 2. Erratum in: *Br J Anaesth*. 2024 Apr;132(4):829. PMID: 37541949.
32. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. *J Clin Endocrinol Metab*. 2019 Aug 1;104(8):3077-3087. doi: 10.1210/je.2019-00139. PMID: 30835263.
33. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol*. 2021 Sep;9(9):586-594. doi: 10.1016/S2213-8587(21)00180-7. Epub 2021 Jul 21. PMID: 34302745; PMCID: PMC8294807.
34. Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. *BMC Endocr Disord*. 2023;23(1):81. doi:10.1186/s12902-023-01339-w.
35. FDA approves label changes to SGLT2 inhibitors regarding temporary discontinuation of medication before scheduled surgery. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious>. Accessed March 23, 2020.
36. BOMSS Patient Safety committee Alert on the use of Gliflozins. <https://bomss.org/clinical-resources/> March 2022.
37. Peri-Procedure Management of Patients on Sodium-glucose cotransporter-2 (SGLT-2) Inhibitors. Published online December 2023. <https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clinical-management-mgmt-sglt2-web-algorithm.pdf>.
38. Selwyn J, Pichardo-Lowden AR. Managing Hospitalized Patients Taking SGLT2 Inhibitors: Reducing the Risk of Euglycemic Diabetic Ketoacidosis. *Diabetology*. 2023;4(1):86-92. doi:10.3390/diabetology4010010.
39. Raiten JM, Morlok A, D'Ambrosia S, Ruggero MA, Flood J. Perioperative Management of Patients Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Development of a Clinical Guideline at a Large Academic Medical Center. *J Cardiothorac Vasc Anesth*. 2024;38(1):57-66. doi:10.1053/jjvca.2023.10.011.
40. Khunti K, Aroda VR, Bhatt DL, Bozkurt B, Buse JB, Heerspink HL, et al. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. *Diabetes Obes Metab*. 2022 Nov;24(11):2071-2080. doi: 10.1111/dom.14805. Epub 2022 Aug 4. PMID: 35801339.
41. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al; on behalf of the American Diabetes Association. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023 Jan 1;46(Suppl 1):S267-S278. doi: 10.2337/dc23-S016. PMID: 36507644; PMCID: PMC9810470.
42. Guideline for Perioperative Care for People with Diabetes Mellitus Undergoing Elective and Emergency Surgery. Published online October 2023. <https://www.cpod.org.uk/sites/cpod/files/documents/2024-03/CPOC-DiabetesGuideline2023.pdf>.
43. Crowley K, Scanall P, Hermanides J, Buggy DJ. Current practice in the perioperative management of patients with diabetes mellitus: a narrative review. *Br J Anaesth*. 2023;131(2):242-252. doi:10.1016/j.bja.2023.02.039.
44. NSW Agency for Clinical Innovation. Use of SGLT2-inhibitors for type 2 diabetes in acute inpatient care: Clinical practice guide. Sydney: ACI; 2023. https://aci.health.nsw.gov.au/_data/assets/pdf_file/0010/825085/ACI-Use-of-SGLT2-inhibitor-medicines-for-people-with-diabetes.pdf.
45. Guidelines of Australian diabetes society. https://www.diabetessociety.com.au/wp-content/uploads/2023/05/ADS-ADEA-ANZCA-NZSSD_DKA_SGLT2i_Alert_Ver-May-2023.pdf.
46. Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations. *Anaesthesia*. 2018;73(8):1008-1018. doi:10.1111/anae.14251.
47. Seki H, Ideno S, Shiga T, Watanabe H, Ono M, Motoyasu A, et al. Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports. *J Anesth*. 2023 Jun;37(3):465-473. doi: 10.1007/s00540-023-03174-8. Epub 2023 Feb 27. PMID: 36849747; PMCID: PMC10229478.
48. Bobrowski D, Kumar R, Wu PE, Lapointe-Shaw L. Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy. *Clin Case Rep*. 2021;9(1):e05057. doi:10.1002/ccr3.5057.
49. Pujara S, Ioachimescu A. Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin. *J Investig Med High Impact Case Rep*. 2017;5(2):2324709617710040. doi:10.1177/2324709617710040.
50. Bonanni FB, Fei P, Fitzpatrick LL. Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin. *Surg Obes Relat Dis Off J Am Soc Bariatr Surg*. 2016;12(1):e11-12. doi:10.1016/j.soard.2015.08.502.
51. Scheen AJ. Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance. *Diabetes Metab*. 2023;49(4):101453. doi:10.1016/j.diabet.2023.101453.
52. Meyer EJ, Mignone E, Hade A, Thiruvengatarajan V, Bryant RV, Jesudason D. Peri-procedural Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy. *Diabetes Care*. 2020;43(11):e181-e184. doi:10.2337/dc20-1244.
53. Hamblin PS, Wong R, Ekinci EI, Sztal-Mazer S, Balachandran S, Frydman A, et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor-Treated Type 2 Diabetes. *Diabetes Care*. 2021 Jun;44(6):e124-e126. doi: 10.2337/dc21-0256. Epub 2021 Apr 25. PMID: 33896795; PMCID: PMC8247528.
54. Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis. *Can J Diabetes*. 2017;41(5):499-503. doi:10.1016/j.cjcd.2017.05.004.